NOVARTIS Australia's Scemblix (asciminib) is now on the PBS for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph CML-CP), previously treated with two or more tyrosine kinase inhibitors (TKIs).
Scemblix is also listed for the treatment of Ph CML in CP with the T315I mutation.
Scemblix is a novel treatment option that works by specifically targeting the ABL myristoyl pocket, also known as a STAMP inhibitor.
This novel mechanism of action offers a reimagined treatment approach for patients who experience intolerance and/or resistance to currently available TKI therapies.
The approval is based on results from the pivotal Phase III ASCEMBL trial.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 May 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 May 23
